^
Association details:
Biomarker:ALK rearrangement
Cancer:Sarcoma
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor

Excerpt:
A 34-year-old woman presented with a painful 3-cm left vulvar-vaginal mass, which was excised and determined to be a sarcoma with positive surgical margins.…testing of her tumor was conducted and demonstrated anaplastic lymphoma kinase gene rearrangements....Treatment with 250 mg crizotinib orally twice daily resulted in complete regression of all visible or palpable tumor within 3 weeks.
DOI:
10.1097/AOG.0000000000001250